Consolidated Statements of Operations (USD $)	12 Months Ended
	Jun. 30, 2013	Jun. 30, 2012
Statements Of Operations [Abstract]
Sales	$ 67,500,476	$ 69,605,758
Cost of sales	41,496,812	45,274,326
Gross profit	26,003,664	24,331,432
Operating expenses
Selling expenses	11,442,664	10,672,817
General and administrative expenses	4,351,592	4,255,528
Research and development	894,995	860,081
Total operating expenses	16,689,251	15,788,426
Income from operations	9,314,413	8,543,006
Other income (expenses):
Interest income	162,563	209,037
Interest expense	(437,897)	(331,334)
Other income		189,268
Total other income (expenses)	(275,334)	66,971
Income before provision for income taxes	9,039,079	8,609,977
Provision for income taxes	2,423,906	2,368,059
Net Income	6,615,173	6,241,918
Less: Net loss attributable to noncontrolling interest	(56,978)	(116,772)
Net income attributable to Tianyin Pharmaceutical Co., Inc.	$ 6,672,151	$ 6,358,690
Basic earnings per share	$ 0.23	$ 0.22
Diluted earnings per share	$ 0.23	$ 0.22
Weighted average number of common shares outstanding:
Basic	29,341,695	29,308,442
Diluted	29,341,695	29,308,442